Citius Oncology, Inc. Operating Expenses
Citius Oncology, Inc. (CTOR) reported Operating Expenses of $9.72 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-14
- Citius Oncology, Inc. operating expenses for the quarter ending 2026-06-30 was $9.72M, a 96.54% increase year-over-year.
- Citius Oncology, Inc. operating expenses for the quarter ending 2026-03-31 was $29.95M, a 300.89% increase year-over-year.
- Citius Oncology, Inc. operating expenses for the quarter ending 2025-12-31 was $8.41M, a 31.47% increase year-over-year.
- Citius Oncology, Inc. operating expenses for the quarter ending 2025-09-30 was $4.71M, a 29.35% decline year-over-year.
- Citius Oncology, Inc. operating expenses for fiscal 2025 was $23.52M, a 14.34% increase from fiscal 2024.
- Citius Oncology, Inc. operating expenses for fiscal 2024 was $20.57M, a 69.72% increase from fiscal 2023.
- Citius Oncology, Inc. operating expenses for fiscal 2023 was $12.12M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.72M 10-Q · filed 2026-08-14 | $39.67M derived: sum of 2 quarters · filed 2026-08-14 | $48.08M 10-Q · filed 2026-08-14 | $52.79M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $29.95M 10-Q · filed 2026-05-15 | $38.36M 10-Q · filed 2026-05-15 | $43.07M derived: sum of 3 quarters · filed 2026-05-15 | $48.02M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $8.41M 10-Q · filed 2026-02-13 | $13.12M derived: sum of 2 quarters · filed 2026-02-13 | $18.06M derived: sum of 3 quarters · filed 2026-08-14 | $25.53M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-09-30 | $4.71M derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-23 | $9.66M derived: sum of 2 quarters · filed 2026-08-14 | $17.13M derived: sum of 3 quarters · filed 2026-08-14 | $23.52M 10-K · filed 2025-12-23 |
| 2025-06-30 | $4.94M 10-Q · filed 2026-08-14 | $12.42M derived: sum of 2 quarters · filed 2026-08-14 | $18.81M 10-Q · filed 2026-08-14 | $25.48M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $7.47M 10-Q · filed 2026-05-15 | $13.87M 10-Q · filed 2026-05-15 | $20.54M derived: sum of 3 quarters · filed 2026-05-15 | $25.16M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $6.39M 10-Q · filed 2026-02-13 | $13.06M derived: sum of 2 quarters · filed 2026-02-13 | $17.69M derived: sum of 3 quarters · filed 2026-02-13 | $22.38M derived: sum of 4 quarters · filed 2026-02-13 |
| 2024-09-30 | $6.67M derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-23 | $11.30M derived: sum of 2 quarters · filed 2025-12-23 | $15.99M derived: sum of 3 quarters · filed 2025-12-23 | $20.57M 10-K · filed 2025-12-23 |
| 2024-06-30 | $4.63M 10-Q · filed 2025-08-12 | $9.32M derived: sum of 2 quarters · filed 2025-08-12 | $13.90M 10-Q · filed 2025-08-12 | |
| 2024-03-31 | $4.69M 10-Q · filed 2025-05-14 | $9.27M 10-Q · filed 2025-05-14 | ||
| 2023-12-31 | $4.58M 10-Q · filed 2025-02-14 | |||
| 2023-09-30 | $12.12M 10-K · filed 2024-12-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |